Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Liraglutide is a prescription glucagon-like peptide-1 receptor agonist. Current generic liraglutide injection labeling includes improved glycemic control in adults and pediatric patients age 10 and older with type 2 diabetes and reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The injection contains 6 mg per mL.
read more about liraglutide ...Liraglutide activates GLP-1 receptors. It increases glucose-dependent insulin secretion, lowers inappropriate glucagon secretion, and slows gastric emptying, which helps reduce blood glucose concentrations.
The diabetes-labeled liraglutide injection is used with diet and exercise in adults and pediatric patients age 10 and older with type 2 diabetes. It is also used to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Coadministration with another liraglutide-containing product is not recommended.
Adults start at 0.6 mg by subcutaneous injection once daily for one week and then increase to 1.2 mg once daily. The dose can increase to 1.8 mg once daily after at least one week at 1.2 mg when additional glycemic control is needed. Pediatric patients age 10 and older also start at 0.6 mg daily and increase in 0.6 mg steps after at least one week at each dose, up to 1.8 mg daily.
Liraglutide carries a boxed warning for thyroid C-cell tumors observed in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other serious concerns include pancreatitis, hypoglycemia, acute gallbladder disease, severe gastrointestinal reactions, kidney injury related to dehydration, severe hypersensitivity, and pulmonary aspiration during general anesthesia or deep sedation.
Current diabetes-labeled injection improves glycemic control in type 2 diabetes from age 10 and reduces major cardiovascular events in selected adults with type 2 diabetes.
The starting dose is 0.6 mg by subcutaneous injection once daily.
The maximum recommended dose is 1.8 mg once daily.
Yes. The boxed warning concerns thyroid C-cell tumors observed in animal studies and the related contraindications.
DailyMed - LIRAGLUTIDE injection. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2100ec49-57b2-4330-ab5f-057ce9b7e4d0. Date Accessed October 13, 2026.
Liraglutide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548472/. Date Accessed October 13, 2026.
Liraglutide Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a611003.html. Date Accessed October 13, 2026.
Liraglutide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Liraglutide. Date Accessed October 13, 2026.
Liraglutide. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK608007/. Date Accessed October 13, 2026.